EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

EGFR inhibition in EGFR ‐mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment

Akihiko Shiiya, Takuro Noguchi iD, Utano Tomaru, Shin Ariga iD, Yuta Takashima, Yoshihito Ohhara, Jun Taguchi, Satoshi Takeuchi, Yasushi Shimizu, Ichiro Kinoshita, Tomonobu Koizumi, Yoshihiro Matsuno und 3 weitere

Cancer Science · 2023-04 · 114 (4) · 1270-1283

DOI: 10.1111/cas.15701 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 26.12.2022. Verfasst von Akihiko Shiiya und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shinshu Igaku Shinkokai, Shinshu University Hospital, The Akiyama Life Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) elicit potent cell cycle arrest in EGFR‐mutant non–small‐cell lung cancer (NSCLC) cells. However, little is known about the mechanisms through which these drugs alter the tumor phenotype that contributes to the immune escape of EGFR‐mutant cells. Using EGFR‐mutant NSCLC cell lines and tissue samples from patients, we investigated the changes in immune checkpoints expressed in tumor cells following EGFR inhibition. Subsequently, we also analyzed the role of soluble factors from the dying tumor cells in the activation of immune signaling pathways involved in therapy resistance. Upon EGFR‐TKI treatment, we found that EGFR‐mutant cells upregulated the expression of innate immune checkpoint CD24 in vitro. We then analyzed biopsy samples from six patients who developed resistance to a first‐generation EGFR‐TKI without the acquired T790M mutation. Immunohistochemistry revealed that levels of tumor CD24 expression were increased upon treatment compared with those from pre‐treatment samples. Monocyte‐derived macrophages facilitated antibody‐dependent cellular phagocytosis when EGFR‐TKI‐treated EGFR‐mutant cells were incubated with anti‐CD24 antibodies in vitro, suggesting that CD24 may be a therapeutical target for EGFR‐mutant lung cancer. Moreover, EGFR inhibition accelerated the release of cell‐free DNA (cfDNA) from dying tumor cells, which activated the type I interferon signaling pathways in human THP‐1 monocytes in a stimulator of interferon genes‐dependent manner. Our study indicates that EGFR inhibition in EGFR‐mutant NSCLC cells fosters a tumor microenvironment associated with immune escape. Thus, CD24 targeted therapy and cfDNA monitoring may contribute to improved treatment outcomes in patients with EGFR‐mutant NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungHumansErbB ReceptorsTumor MicroenvironmentProtein Kinase InhibitorsMutationDrug Resistance, NeoplasmSignal Transduction

Stichwörter der Autor:innen

CD24EGFR-TKIsEGFR-mutant NSCLCcfDNAtumor immune escape

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
  • Department of Hematology and Medical Oncology, Shinshu University School of Medicine, Matsumoto, Japan.
  • Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Japan.
  • Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Division of Clinical Cancer Genomics, Hokkaido University Hospital, Sapporo, Japan.

ORCID-Profile: Takuro Noguchi, Shin Ariga, Jun Sakakibara-Konishi

Förderung

  • Shinshu Igaku Shinkokai
  • Shinshu University Hospital
  • The Akiyama Life Science Foundation
  • The Ministry of Education, Culture, Sports, Science and Technology of Japan

Zitieren

APA

Shiiya, A., Noguchi, T., Tomaru, U., Ariga, S., Takashima, Y., Ohhara, Y., Taguchi, J., Takeuchi, S., Shimizu, Y., Kinoshita, I., Koizumi, T., Matsuno, Y., Shinagawa, N., Sakakibara-Konishi, J., & Dosaka-Akita, H. (2023). EGFR inhibition in EGFR ‐mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment. Cancer Science, 114(4), 1270-1283. https://doi.org/10.1111/cas.15701

Vancouver

Shiiya A, Noguchi T, Tomaru U, Ariga S, Takashima Y, Ohhara Y, et al. EGFR inhibition in EGFR ‐mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment. Cancer Science. 2023;114(4):1270-1283. doi:10.1111/cas.15701

BibTeX
@article{Shiiya2023,
  author = {Shiiya, Akihiko and Noguchi, Takuro and Tomaru, Utano and Ariga, Shin and Takashima, Yuta and Ohhara, Yoshihito and Taguchi, Jun and Takeuchi, Satoshi and Shimizu, Yasushi and Kinoshita, Ichiro and Koizumi, Tomonobu and Matsuno, Yoshihiro and Shinagawa, Naofumi and Sakakibara-Konishi, Jun and Dosaka-Akita, Hirotoshi},
  title = {EGFR inhibition in EGFR ‐mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment},
  journal = {Cancer Science},
  year = {2023},
  volume = {114},
  number = {4},
  pages = {1270--1283},
  doi = {10.1111/cas.15701}
}
Kostenlos starten →